Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026
Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026
截至2023年12月31日，Quince Therapeutics报告了7,510万美元的现金，预计将通过第三阶段NEAT收入业绩为主导资产EryDex提供全额资金，并为2026年可能提交的保密协议做准备
Strong Cash Position Expected to Support Meaningful Clinical Milestone
强劲的现金状况有望支持有意义的临床里程碑
- Reported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing cash runway to be sufficient to fund the company's capital efficient development plan into 2026.
- 截至2023年12月31日，报告的现金、现金等价物和短期投资为7,510万美元。昆斯预计，其现有的现金流将足以为该公司2026年的资本效率发展计划提供资金。
- Expect to fully fund lead asset, EryDex, through Phase 3 NEAT topline results and prepare for a potential NDA submission in 2026, assuming positive study results. This includes approximately $20 million for the NEAT study and approximately $15 million in direct trial costs for the open label extension.
- 假设研究结果良好，预计将通过NEAT的第三阶段业绩为主要资产EryDex提供全额资金，并为2026年可能提交的保密协议做准备。这包括用于NEAT研究的大约2000万美元以及开放标签扩展的约1500万美元的直接试验费用。
- Evaluate potential strategic partnerships to out-license ex-U.S. regional territories to extend operational runway to support potential NDA approval of EryDex, as well as further advance other potential indications and programs discovered using the AIDE platform.
- 评估潜在的战略合作伙伴关系，以超越美国前地区领土的许可，以延长运营跑道以支持EryDex的潜在保密协议批准，并进一步推进使用AIDE平台发现的其他潜在适应症和计划。